Incyte is dolloping another deal onto its 2024 partnership plate, buying San Diego-based Escient Pharmaceuticals for $750 million. The...

Acquisition transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end...

Initial studies will focus on infants and young children; company plans to begin clinical trials in the United States and Australia in...

Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant...

10,000 participant randomized Phase 2b study will evaluate Gritstone’s self-amplifying mRNA (samRNA) vaccine candidate containing Spike...

Funding will advance pipeline of 17 existing programs and approximately 10 new starts annually Company has raised nearly $700 million in...

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif., June 20, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and DICE Therapeutics, Inc....

Data Presented at Late-Breaking Session at Heart Rhythm Society 2023: Paves Way for Premarket Approval Application for Federal Drug...

Multi-year collaboration will facilitate the co-development of optimized therapeutics that bind to challenging targets in ways...